BioCentury
ARTICLE | Clinical News

ABBV-974: Phase I data

October 19, 2015 7:00 AM UTC

A double-blind, placebo-controlled, Belgian Phase I trial in about 64 healthy volunteers showed that single doses of 30-2,000 mg oral GLPG1837 and twice-daily 125-800 mg doses of oral GLPG1837 for 14 ...